• Alias: ABT-888
    • A PARP-1 and -2 inhibitor that inhibits DNA repair and potentiating the cytotoxicity of DNA-damaging agents
    • Phase 2/3 in combination with temozolomide in newly diagnosed glioblastoma multiforme; phase 2 in combination with atezolizumab in stage III to IV triple-negative breast cancer; phase 2 in combination with FOLFOX-6 or XRT in locally advanced rectal cancer
    • Recommended dose: 120 to 150 mg PO b.i.d. in combination with chemotherapy
    • Half-life: 5 to 6.5 hours
    • Common side effects: Nausea, fatigue, mild myelosuppression
    (Gojo et al., 2017)
    Other topics in Targeted and Immunotherapy Agents